| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-11-12 | masitinib in combination with etoposide, or with irinotecan | advanced hepatocellular carcinoma | 2 | AB Science (France) | Cancer - Oncology |
| 2014-11-12 | OTX015 | advanced solid tumors (BRD-NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer harbouring a rearrangement ALK gene/fusion protein or KRAS mutation, Castrate-Resistant Prostate Cancer, Pancreatic Ductal Carcinoma) | 1b | OncoEthix (Switzerland) | Cancer - Oncology |
| 2014-11-11 | CardiAMP | heart failure |
3 | BioCardia (USA - CA) | Cardiovascular diseases |
| 2014-11-11 | Diamyd® (glutamic acid decarboxylase - GAD) and Gamma-Amino Butyric Acid (GABA) | type 1 diabetes | 1 | Diamyd Medical (Sweden) University of Alabama at Birmingham (USA - AL) | Autoimmune diseases - Metabolic diseases |
| 2014-11-11 | sofosbuvir and velpatasvir (GS-5816) | chronic hepatitis C virus infection | 2 | Gilead Sciences (USA - CA) | Infectious diseases |
| 2014-11-11 | Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg) | chronic hepatitis C |
2,3 | Gilead Sciences (USA - CA) | Infectious diseases |
| 2014-11-11 | grazoprevir/elbasvir | chronic hepatitis C infection |
2 | Merck&Co (USA - NJ) | Infectious diseases |
| 2014-11-11 | ALN-HDV | chronic hepatitis delta virus (HDV) infection |
Alnylam Pharmaceuticals (USA - MA) | Infectious diseases | |
| 2014-11-11 | ALN-PDL | chronic liver infections |
Alnylam Pharmaceuticals (USA - MA) | Hepatic diseases - Liver diseases - Infectious diseases | |
| 2014-11-11 | ABT-450/ritonavir and ombitasvir | hepatitis C |
b | Abbvie (USA - IL) | Infectious diseases |
| 2014-11-11 | ALN-HBV | hepatitis B |
Alnylam Therapeutics (USA - MA) | Infectious diseases | |
| 2014-11-11 | ARGX-110 | patients with relapsed/refractory CD70-positive T-cell lymphomas |
1b | Argen-X (Belgium) | Cancer - Oncology |
| 2014-11-11 | GV2311 | Respiratory Syncytial Virus (RSV) infection | preclinical | Genvec (USA - MD) | Infectious diseases |
| 2014-11-10 | tivantinib | prostate cancer | 2 | Arqule Therapeutics (USA - MA) | Cancer - Oncology |
| 2014-11-10 | Civacir® | hepatitis C |
3 | Biotest (Germany) | Infectious diseases |
| 2014-11-10 | ONT-10 and Varlilumab | 1b | Oncothyreon (USA - WA) Celldex Therapeutics (USA - NJ) | Cancer - Oncology | |
| 2014-11-10 | daratumumab in combination with bortezomib, thalidomide and dexamethasone | frontline multiple myeloma | 3 | Janssen Biotech - J&J (USA - NY), French Intergroup of Myeloma (IFM) (France), Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) (Belgium - The Netherlands | Cancer - Oncology |
| 2014-11-10 | 4Kscore Test | prostate cancer |
OPKO Health (USA - FL) | Cancer - Oncology | |
| 2014-11-10 | Zonegran® (zonisamide) | paediatric partial onset seizures in children with partial epilepsy |
Eisai (Japan) | CNS diseases - Neurological diseases | |
| 2014-11-08 | daclatasvir and sofosbuvir | genotype 3 hepatitis C (HCV) patients |
3 | BMS (USA - NY) | Infectious diseases |
